These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34854557)

  • 1. An ACVR1
    Kaplan FS; Groppe JC; Xu M; Towler OW; Grunvald E; Kalunian K; Kallish S; Al Mukaddam M; Pignolo RJ; Shore EM
    Am J Med Genet A; 2022 Mar; 188(3):806-817. PubMed ID: 34854557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclassic fibrodysplasia ossificans progressiva: A child from Angola with an ACVR1
    Martín-García D; Towler OW; Xu M; Alfonso-Hernández O; Oliveira PR; Alonso-Clavo M; Shore EM; Kaplan FS
    Am J Med Genet A; 2021 Aug; 185(8):2572-2575. PubMed ID: 33973349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients.
    Kaplan FS; Kobori JA; Orellana C; Calvo I; Rosello M; Martinez F; Lopez B; Xu M; Pignolo RJ; Shore EM; Groppe JC
    Am J Med Genet A; 2015 Oct; 167A(10):2265-71. PubMed ID: 26097044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
    Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
    Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report.
    Nakahara Y; Katagiri T; Ogata N; Haga N
    Am J Med Genet A; 2014 Jan; 164A(1):220-4. PubMed ID: 24259422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene.
    Cappato S; Traberg R; Gintautiene J; Zara F; Bocciardi R
    Mol Genet Genomic Med; 2021 Oct; 9(10):e1774. PubMed ID: 34347384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
    Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
    J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
    Towler OW; Shore EM
    Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1
    Maruyama R; Nguyen Q; Roshmi RR; Touznik A; Yokota T
    Nucleic Acid Ther; 2022 Jun; 32(3):185-193. PubMed ID: 35085461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
    Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
    J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
    Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
    Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.
    Collins MT
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.
    Kaplan FS; Al Mukaddam M; Stanley A; Towler OW; Shore EM
    Bone; 2020 Nov; 140():115539. PubMed ID: 32730934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.
    Towler OW; Shore EM; Xu M; Bamford A; Anderson I; Pignolo RJ; Kaplan FS
    Eur J Med Genet; 2017 Jul; 60(7):399-402. PubMed ID: 28473268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
    Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
    J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.